Teva Pharmaceutical Industries LTD Form 4 insider transactions

Director Janet S. Vergis reports the vesting and disposal of restricted share units resulting in the acquisition and disposal of ordinary shares of Teva Pharmaceutical Industries.

Director Gerald Lieberman reports the vesting and conversion of restricted share units into ordinary shares of Teva Pharmaceutical Industries.

Director Amir Elstein reports the vesting and subsequent disposal of restricted share units resulting in the acquisition of ordinary shares.

Director Sol J. Barer reports acquiring 37,598 ordinary shares of Teva Pharmaceutical Industries through the vesting of restricted share units on June 15, 2024.

Director Varda Shalev reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries on June 6, 2024.

Director Tal Zvi Zaks reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd, reported the acquisition of 9,632 restricted share units on June 6, 2024, which vest on June 6, 2025.

Director Ronit Satchi-Fainaro acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Director Roberto Mignone acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Director Perry Nisen acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Director Gerald Lieberman acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Director Janet S. Vergis reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

Director Amir Elstein reports acquisition of 9,632 restricted share units in Teva Pharmaceutical Industries Ltd.

Director Sol J. Barer reports acquisition of 17,158 restricted share units in Teva Pharmaceutical Industries, vesting on June 6, 2025.

EVP of Global Operations at Teva Pharmaceutical Industries, Matthew Shields, reports acquisition of restricted share units convertible to ordinary shares.

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, sold a total of 28,135 ordinary shares in two transactions on May 15 and 16, 2024.

Vikki L. Conway, Acting Head of Global Human Resources at Teva Pharmaceutical Industries, sold 15,219 ordinary shares at an average price of $16.7427 on May 13, 2024.

EVP and CFO of Teva Pharmaceutical Industries, Eliyahu Sharon Kalif, reports the vesting of restricted share units and subsequent sale of ordinary shares under a pre-arranged trading plan.

Executive VP of Global Operations at Teva Pharmaceutical Industries, Eric Drape, reports acquisition of ordinary shares through restricted share unit vesting.

Executive VP Richard Daniell reports the vesting of restricted share units (RSUs) and subsequent sale of shares to cover tax obligations, alongside sales under a pre-arranged 10b5-1 trading plan.

Vikki L. Conway, Acting Head of Global Human Resources at Teva Pharmaceutical Industries, sold shares to cover tax withholding obligations related to vesting restricted share units.

EVP, International Markets at Teva Pharmaceutical Industries, Mark Sabag, reports acquisition and disposal of ordinary shares and restricted share units.

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent disposal of ordinary shares.

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, was granted 66,964 restricted share units on March 4, 2024, according to a Form 4 filing.

Vikki L. Conway, an officer at Teva Pharmaceutical Industries, reported the acquisition and disposal of ordinary shares and restricted share units.

Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries, was granted 81,845 restricted share units on March 4, 2024.

EVP of Business Development at Teva Pharmaceutical Industries, Angus Grant, reports acquisition of 52,083 restricted share units on March 4, 2024.

Richard Francis, CEO of Teva Pharmaceutical Industries, reports the acquisition and disposal of ordinary shares and restricted share units, including sales to cover tax obligations, under a pre-arranged Rule 10b5-1 trading plan.

Executive VP of Global Operations at Teva Pharmaceutical Industries, Eric Drape, reports the vesting and disposal of restricted share units, resulting in the acquisition of ordinary shares.

Executive VP Richard Daniell reports acquisition and disposal of Teva Pharmaceutical Industries Ltd. ordinary shares and restricted share units.